Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline for excessive daytime sleepiness in Parkinson's disease
2012-001530-34Phase 3Terminated
- Sponsor
- VU University Medical Center
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of varenicline in Parkinson's disease (PD) and Excessive Daytime Sleepiness (EDS) (2 arms), sponsored by VU University Medical Center. Primary endpoint: Change in excessive daytime sleepiness (ESS). Started Aug 2012; status: terminated.
02
Drugs
varenicline
03
Conditions
Parkinson's disease (PD)Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on 2012-001530-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001530-34.